Broader view of thingsThe whole process of re- aligning financial opportunities, needs to be seen in proper context.
Some yamner on about dillution, lack of deals etc .
First, as I stated the recent announcement is a Cary forward of existing ATM, only changing the agent.
NOT as additional amount.
Second, the point of dillution?
unless anothe4 source of $$ comes up, they need to raise funds to keep the business running.
Dillution only matters undef a few scinarios.
1. If they pay dividends , which they don't.
2. on an overall company buyout. ...They coman6 would be bough5 based on present value if future income/ number of shares.
so, the real question is, can they create more company value to off set the number of shares?
Listening to the Q2 results, the following statement justifies, keeping the doors open.
" positive overall survival resukts from bracelet MBc study, expected before end of this year, will strengthen our negotiation position"
simple answer.
assuming they did not source $$ by usdu8ng shares... then they would have to negotiate from a position of weakness &/ or close down.
meaning shareholder value would be minimal.
assuming the MBc resukts come in as expected, then they can negotiate from a stronger position.
The on going additional arm of pancreatic cancer treatment alone , could lead to a third registration trial.
again, increasing potential value of the company.
All markets are all over the place right now.
like all opportunities, sometimes hard to see.
equally as hard to buy in.. lots of fear right now.
those who can only see value of a company based in its shareprice. Vs potential value of shareprice,
ONC potential?
We will see that unfold once the MBc O.S. Numbers are made public.
until then, at the mercy of the market.
reminder.
The onkybreason Onc exists is to get Pelareorep approved for cancer treatment.
right now, as you read this they have strong support from CGAR, based on phase 2 pancreatic trial results.
Both the MBc & panc cancer phase 2 trials resulted in FDA fast track designstion.
I could go on.
point being Onc is worth a lot more than what it is trading at.
and potentially multiples higher in the near future.